ACR Releases New JIA Treatment Guidelines

Below is a press release from ACR dated May 13, 2026:

The American College of Rheumatology (ACR) released updated guidelines for the treatment and management of juvenile idiopathic arthritis (JIA). These guidelines are companions to previously updated JIA guidelines released by the ACR in 2019 and 2022 and this update covers several types of juvenile idiopathic arthritis including polyarthritis, oligoarthritis, TMJ arthritis, enthesitis and dactylitis. Juvenile idiopathic arthritis related uveitis was also addressed as well as selected topics in non-pharmacologic management and imaging.

“The guidelines encourage early use of DMARDs with attention paid to risk factors that would suggest the need for early escalation of treatment. To that end, use of biologic DMARDs without the requirement of “failure” of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was supported. Any required waiting period is too long if a child is not doing well,” said Karen Onel, MD, Chief of the Pediatric Rheumatology Division at the Hospital for Special Surgery in New York and the lead investigator of the guidelines. “Balancing treatment with careful screening for side-effects will allow for the best outcomes.”

The overarching goals of the updated guidelines are to promote early and aggressive treatment of JIA that preserves function and maximizes quality of life, encourage timely screening and monitoring to prevent articular and extra-articular damage, and facilitate effective shared decision-making among clinicians, patients, and caregivers.

“Many children in the US and around the world do not have access to expert pediatric rheumatology care. These guidelines should assist not only pediatric rheumatologists but adult rheumatologists and pediatricians in choosing best treatment for children with JIA.” said Dr. Onel. “Recommendations supporting the use of oral over subcutaneous methotrexate is a change from previous standard of care. Continued decreased reliance on NSAIDs and glucocorticoids has been emphasized. Recommendations have been made for mental health care in keeping with recent ACR guidance.

Like many other ACR guidelines, the updated guidelines for JIA were developed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which creates rigorous standards for judging the quality of the literature available and assigns strengths to the recommendations. The papers containing the full list of recommendations and supporting evidence are available on the ACR’s guideline page.

Lupus Identified as a Leading Cause of Years of Potential Life Lost in Young Women

Below is a press release dated May 7, 2026 from ACR:

New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant and often underrecognized public health burden.

The study, titled “Lupus, a leading cause of years of potential life lost in young women: implications for public health priorities and research funding,” published in ACR Open Rheumatology, finds that lupus disproportionately affects women during their most productive years, contributing to premature mortality and long-term societal impact.

Years of potential life lost (YPLL) is a key public health metric that measures premature death. The study shows that lupus ranks among the top causes of YPLL in young women. This study adds to the authors’ previous work that showed that lupus is among the leading causes of death —particularly among Black, Hispanic, and other historically underserved populations—highlighting persistent health disparities.

“These findings reinforce what the rheumatology community has long observed: lupus is not only a chronic disease but a life-threatening condition that cuts lives short,” said lead researcher Ram Raj Singh, M.D. at the David Geffen School of Medicine at the University of California at Los Angeles (UCLA).  “Despite this, it remains underfunded relative to its impact.”

Key findings from the study include:

  • Lupus is a leading contributor to premature mortality among women of reproductive age.
  • The societal and economic costs of lupus are amplified by its impact during peak working and caregiving years.

The authors emphasize that the findings should prompt policymakers and research agencies to re-evaluate funding priorities. Despite its high burden, lupus research funding has historically lagged behind other diseases with comparable or lower YPLL.

Advocates say the study strengthens the case for:

  • Increased federal investment in lupus research through agencies such as the National Institutes of Health (NIH).
  • Expanded access to early diagnosis and specialized care.
  • Development of safe, effective, and affordable treatments for lupus.
  • Public health initiatives aimed at reducing disparities and improving outcomes in high-risk populations.

“Addressing lupus requires a coordinated national strategy,” said Andras Perl, MD, PhD, Editor-in-Chief of ACR Open Rheumatology. “We have an opportunity to save lives by investing in research, improving access to care, and raising awareness of this devastating disease.”

Lupus is a chronic autoimmune disease in which the immune system attacks healthy tissues, leading to inflammation and damage across multiple organ systems. There is currently no cure.

Text states "The Patient Voice: What I Wish My Rheumatology Care Team Knew." There is a rainbow graphic on the slide alongside a photo of Grayson from 1993 where he is exhaustedly sleeping on the couch.

Presenting at #ACR25

In 1993, I was five years old. By mid-November, I developed an itchy rash of unknown origin along with fatigue, joint pain, and swelling.

It took 8 months — along with a host of misdiagnoses, including leukemia — before I was diagnosed with Systemic Juvenile Idiopathic Arthritis / Juvenile-Onset Still’s Disease.

My whole life has, for better or worse, been defined by having a rare condition. I had to become an expert in it in order to survive into my 30s… which is something I frankly didn’t count on for most of my life.

Tomorrow afternoon, I get to co-present a session at the American College of Rheumatology’s Annual Meeting alongside some of my favorite people. Presenting in the same space as the superheroes who take care of patients and change lives every single day is something I never could’ve imagined as a kid. It’s humbling and awe-inspiring and, honestly, something that’s been on my professional bucket list.

Our session, “Breaking Barriers: Advancing LGBTQIA+ Inclusion in Rheumatology,” explores how we can make rheumatology practice and research more inclusive. I’ll also share what it’s like living rurally with multiple rare conditions while being queer and trans.

We’ll be presenting virtually, and the session will be available on-demand for anyone attending ACR to view later.

This milestone means a lot to me, both personally and professionally. It’s also vital in the trying times we find ourselves in. If you’re attending ACR, I’d love for you to tune in if you can.

5 Months After Approval, I Still Don’t Have Ilaris – And I’m Not Okay

I’m an expert on Still’s Disease, both as a researcher and as someone living with it since childhood.

Despite this, I’ve spent the past six months fighting to access the biologic medication that keeps my rare autoinflammatory disease in check. Short of explaining all the ways Still’s Disease is terrifying, this medication literally keeps me both stable and alive.

After six month of fighting, I still don’t have it.

My uncontrolled disease is running rampant. The excess inflammation is worsening the bulging cervical discs I have, causing immense pain on top of endless frustration.

Between a self-funded insurance plan through my spouse’s employer, the plan’s administrator Employee Benefits Service Center, delays from the pharmacy benefit manager TrueScripts, and a lack of urgency from those with the power to help, I may not receive my medication before traveling to Spain next week for the OMERACT meeting — a meeting focused on improving health outcomes for rheumatology patients.

Despite my relentless efforts to navigate the system, I’ve been met with silence, slow responses, shifting responsibility, and even apathy.

This never should’ve happened in the first place.

I was previously receiving Ilaris from the Novartis patient assistance program. They ended these programs for anyone with private insurance at the end of 2024, leaving countless patients like me without a safety net and in excruciatingly declining physical and emotional health.

If someone like me — someone who knows the disease, the system, how to advocate — has this much trouble accessing essential care, I can’t help but wonder how many others are quietly struggling or have been forced to switch back to a medication that was not effective. Despite how people view me as positively stubborn, I’ve been struggling with feeling forgotten, dismissed, and being too exhausted or in pain to handle all of this.

I don’t know what else to do anymore. The hundreds of hours I’ve spent coordinating between my provider, the PBM, the insurance plan administrators, and even my spouse’s HR representative all feel like they’ve been for nothing.

What I do know is that this isn’t right. This system must change, and it has to prioritize people’s lives over profits.

Patients deserve better. I deserve better — especially when the consequences of not having medication can be fatal.

If I die because of this ongoing lack of treatment, scatter my body parts in front of all these company’s locations.

Note: Everything I share here reflects my personal experience and views — not those of my employers, collaborators, or any organizations I am affiliated with. I’m speaking for myself, sharing a deeply real, painful, and ongoing struggle that has taken an immense toll on my health, my hope, and the joy I had for this year.

Where I’ve Been

Many of you may know that I have hypermobile Ehlers Danlos Syndrome (hEDS). For the last 6 months, I’ve been dealing with a complication of this condition, called Craniocervical instability (CCI).

May be an image of text that says 'Hyperextension Hyperflexion KGEE Sprain or strain of cervical tissues'
Image description: An image of neck hyperextension and hyperflexion, which can both lead to sprain or strain of cervical (neck) tissues. (source)

My neck, my legs, and my pain levels

In December, I wound up with what we figured was a pinched nerve. One of my healthcare providers told me this was just unprocessed trauma showing up in my body. It took me switching to a new primary care provider who also has EDS for my neck issues to be taken seriously.

I had an MRI on April 1st, which showed that I now have two bulging discs in my neck.

Complicating matters is that it’s taken FIVE MONTHS for my insurance to agree to cover a medication for my Still’s Disease. I don’t have it yet, but hopefully I will this next week. They don’t want to cover this medication because it’s expensive. It’s also one of only 3 medications that treats this rare disease. I’ve already been on one of the others which stopped being as effective for me after having been on it for nearly a decade.

The extra inflammation in my body because of not having my medication is making my neck MUCH worse, to the point where the discs are booping my spinal cord. This happens occasionally, but more often than before. On top of the nerve pain this causes — which can’t be touched by any pain medication — my body is less coordinated than normal. I drop things a lot and run into things more often. The nerves in my back begin to fire all at once if I get overheated or do too much without taking a break, especially if I’m using my arms a lot. Like I said, there’s no way to attack that pain with medications.

The only way out of it is through. Sometimes that means sitting down for 5 minutes or writhing in pain for an hour.

 

Surgery isn’t really an option – yet

Because of having CCI and hEDS, surgery to fix this won’t fix the underlying issue. I also have Mast Cell Activation Syndrome, which reacted so badly with general anesthesia when I had top surgery that I nearly died.

So, surgery isn’t an option… for now. It won’t be until this gets completely unsustainable. And that’s if I could find a surgeon who would be knowledgeable about my conditions and willing to take on the risks.

I’m working with my EDS-focused physical therapist and my primary care doctor on what to do now. CCI often benefits from physical therapy. I’m not able to see my EDS PT as often as I need to, though. I also see her virtually, which is usually great. For this, though, I need to find someone to see in person. That person needs to know how to handle CCI and be willing to learn about EDS. Otherwise, I’m putting myself at risk of further injury.

 

How I’m doing

Again, I’m dealing with a lot of pain. I’ve had chronic pain since I was 5, but this is a whole different ball game. With my neck being unstable already and the lack of access to my medication, I already wasn’t going out and doing a lot. Now with the bulging discs, though, I have to be very mindful of how I support my neck. I generally have a maximum of 2 hours of sitting upright in me before I have to rest and make sure that I’m supporting my neck by using a neck brace, propping up my neck with my hands, laying down, or leaning back against a chair or couch.

This is also causing a lot of muscle spasms. I have to roll out my leg muscles every single night before I go to be on top of taking a muscle relaxer. This has eased up slightly with starting a number of vitamin supplements, but is still an ongoing issue. If I don’t do these things, my leg muscles lock up and I can’t sleep.

I’m… very tired. I’m tired of fighting insurance on getting my medication covered. This is something they said they would do back on January 30, but keep putting roadblocks in our way. I’m exhausted from having to constantly think through what I want to do and consider if it will cause my body issues. Though, I’m also just as frustrated about trying to do things and not being able to or causing myself pain in the process.

A photo of Grayson face-on. He is sitting on a couch with his left arm supporting his neck.
Image description: A photo of Grayson face-on. He is sitting on a couch with his left arm supporting his neck.

I’m very grateful to have the best two helper dogs in Hank and Dean.

Hank (left) and Dean (right) look out the front window of our house while on the couch. They are black-and-white smaller sized mixed breed dogs.
Image description: Hank (left) and Dean (right) look out the front window of our house while on the couch. They are black-and-white smaller sized mixed breed dogs.

I’m also honestly feeling worried about my spouse. This is a lot of stuff all at once. The balance between being a partner and a caregiver is a hard one to deal with. It’s overwhelming for me, absolutely. I don’t have the added helplessness of not being able to do anything about it.

 

Moving forward

We’re heading to Spain in a few weeks. I’ll be attending the 2025 OMERACT conference.

I’m honestly not sure how traveling will go, let alone attending sessions.

Thankfully, I’ll be among friends and world-renowned rheumatologists. It’s probably one of the best places to be with how my body is right now.

If I know you in real life, don’t stop inviting me to things. I can’t guarantee I’ll be able to attend anything, really. But, I still appreciate being included.

If I don’t know you in real life? IDK. Send happy thoughts my way, maybe?

a red-filtered hand in pain with text next to it: "Unifying SJIA and Still’s disease"

Unifying SJIA and Still’s disease

EULAR and PReS have published a journal article detailing “the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease.”

This combination will help to solidify that SJIA and AOSD are the same disease. It will also help clarify what treatment should look like, for those who have decent access to healthcare. The author issue 14 recommendations, with 3 on diagnosis, 2 on treatment timing, 3 on treatment options, and the rest focused on complications and issues to watch out for.

Check out the Medical Xpress article that goes into a high-level look at the article. You can also check out the full open-access article itself.

DeepCure’s AI Platform Creates Novel Brd4 Inhibitor

The following is an excerpt of an article on Drug Discovery Trends, dated 9/9/2024:

The company’s first AI-generated drug candidate, DC-9476, a selective Brd4 BD2 inhibitor, embodies this approach, showing promise in preclinical models of autoimmune diseases like rheumatoid arthritis (RA) and Still’s disease. In RA models, DC-9476 demonstrated superior efficacy compared to standard treatments, including TNF-alpha inhibitors, IL-6 inhibitors, and the JAK inhibitor tofacitinib. DeepCure recently announced a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) to test DC-9476 in RA.

Read the full article here

ACR Encourages Patients to Implement Self-Management Strategies #RDAM

The following is a press release from ACR dated September 9, 2024:

The ACR Encourages Patients with Rheumatic Diseases to Implement Self-Management Strategies to Improve Quality of Life

American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not as prevalent as it should or could be despite the improvements patients experience when implemented. This is due, in part, to many patients lacking awareness and motivation to self-manage and thinking the only way to control their disease is by taking their medication.

Today, the ACR launched its patient education campaign, Self-Management for Patients Living with Rheumatic Conditions for Rheumatic Disease Awareness Month (RDAM)The campaign addresses the current knowledge gap, educates patients about self-management techniques, and encourages them to collaborate actively with their rheumatology healthcare team to manage their rheumatic condition.

The campaign does not delve into self-care practices yet focuses on self-management strategies for managing a patient’s rheumatic condition.

“One thing that is important to note is that self-management is often used interchangeably with self-care, but they are different. Self-management is an individual’s day-to-day management of their chronic conditions over the course of an illness,” says Bhakti Shah, MD, a rheumatologist with Crystal Run Healthcare in Middletown, N.Y., and the campaign’s medical spokesperson. “Self-care consists of those tasks performed by healthy people to prevent illness rather than manage an existing illness.”

The campaign highlights five overarching strategies patients can incorporate in their lives. They are:

  • Stress Management –Rheumatic conditions can impact a person’s physical and mental health. Patients can create relaxation practices like meditation, self-reflection, or journaling.
  • Medication Adherence –Patients should partner with a clinician to understand their medications, what aspects of their disease they treat, and the importance of continuing these medications.
  • Lifestyle Changes –Regular exercise and eating a healthy diet are essential for general well-being and may help improve symptoms.
  • Communicate and Collaborate with a Healthcare Team –Patients should maintain open communication with their rheumatology healthcare team, including the rheumatologist, physical therapist, and other specialists.
  • Maintain a Support System—Patients should ask family or friends for help when needed, especially during a flare.

“Each patient encounter is an opportunity for rheumatologists (and rheumatology health professionals) to remind patients to incorporate self-management techniques in their lives. During my patient visits, I try to review topics such as medication adherence, physical activity and quality of life and I remind them that we are a team and collaboration will lead to improved outcomes for them,” Dr. Shah continues. “We hope this campaign will empower patients to take a more proactive role in their treatment journey.”

Rheumatic Disease Awareness Month is recognized each September, drawing attention to more than 100 conditions under the umbrella of rheumatic diseases. Rheumatoid arthritis, osteoarthritis, and lupus are some of the most commonly known. Others include Sjögren’s syndrome, gout, scleroderma, and psoriatic arthritis. More than 53.2 million American adults—one in four—have been diagnosed with rheumatic disease.

To view the full self-management toolkit, visit www.RDAM.org.

I caught COVID (and it's still horrible)

I Caught COVID (and it’s still horrible)

At the beginning of this month, my partner and I attended a super-spreader event — GenCon. We masked the entire time, unless we were eating. But, those one-way protections were still not enough to save us.

On the evening of Saturday the 3rd, while still there, my partner tested positive for COVID after only having minor runny nose symptoms and a tickle in their throat.

We drove home overnight. On Sunday, we got them to urgent care for a script of Paxlovid.

Knowing that my positive test would come within days, I spent some of my energy Monday to wrangle a Paxlovid script for myself, which I started on the 6th. It was a good thing, too, as my symptoms really hit hard on the morning of the 6th.

I woke up with a gunky throat, small cough, and some intense chills.

My Paxlovid tips: Take Paxlovid with some food already in your stomach. Follow it up with a lot of water and some more food. These things will help limit the horrid taste that will otherwise float up your throat and into your mouth… and make you want to vomit.

The bulk of my infection was relatively normal. I napped here and there. I had some nasty heartburn.

After sleeping 18/24 hours Saturday and finishing my Paxlovid Sunday, I was finally feeling better — not 100%, but probably 75-80% physically and 90% mentally.

I was very grateful my illness hit a couple days following my partner’s, and that their mom watched the dogs for a few extra days.

By Monday the 12th, I was asymptomatic and testing negative. I still rested a lot over the week, as to not tempt the long COVID deities.

On Thursday evening, I was supposed to fly out to Atlanta to attend the National LGBTQ Health Conference. I woke up that morning with a runny nose, which I had attributed to missing a dose of allergy medication the night before.

But, after hearing about someone else dealing with possible COVID symptoms, I took a home test… which was heavily positive. That line was THICK. A second home test showed positive, too. After a few minutes of crying, I headed over to urgent care for a confirmation PCR test. 

And, of course, I’m in the 20% of people who get rebound COVID.

I canceled my travel plans.

Folks at urgent care were really delightful, and I had wonderful interactions with everyone there. We decided against another round of Paxlovid, mostly because there isn’t much evidence to prove that it’s helpful. The real trick is to just treat and monitor symptoms.

I spent a little over an hour canceling my travel plans and preparing for another several days of isolation.

By the evening, my left eye was leaking sinus fluid along with my left nostril. My left eye was also beginning to swell.

Halfway through the day on Friday, I began to itch all over. By the evening, I figured this was a COVID-related rash, as that’s not uncommon in rebound infections especially. It was bad enough that I had to take dye-free Benadryl to help. My partner drew me a nice, warm bath to relax in for a while, too.

When I woke up at 3:45 am, my Benadryl had worn off… and my whole body was swollen and covered in rash. And that was after two regular antihistamines, adding in another allergy med, dye-free Benadryl, and using my Benadryl anti-itch spray.

My left eye was horribly worse, too.

Grayson with a swollen left eye

After lying awake on my couch for half an hour waiting for another Benadryl to kick in, I began to really grapple with the idea that this rebound COVID infection had sent me into a full-on Still’s Disease flare-up.

Knowing that COVID can cause cytokine storms — and that’s essentially what Macrophage Activation Syndrome is — I had to get medical attention.

I wasn’t bad enough to feel like an ER trip was warranted. So, I set up an urgent care appointment Saturday at 10:30 am. And, I’m glad I did. My rash and swelling continued to progress through the early morning hours. My skin felt bruised because of the inflammation, and my left eye was so swollen that I could not easily find my occipital bone.

For the first time, someone at urgent care KNEW Still’s, and agreed that I needed a prednisone burst. He even asked what dosage I usually start at.

As a rare disease patient, I’m so used to being dismissed or having to completely explain my condition(s) to providers. The fact that I didn’t have to do that felt revolutionary. My Quality of Life went from 4 to 8 over the course of a few hours.

And, honestly? I wanted to cry.

Within just an hour of starting prednisone, my eye got less puffy and I was generally less swollen. My fingers, hands, and wrists were still swollen, but much less so. And, most importantly, I was no longer covered in rash (although I still had a few spots).

When I woke up Sunday, after a full night’s sleep, I was covered in rash again. Thankfully, it was nowhere near as bad as the day before. It easily dissipated after I waited for steroids to kick in. Unfortunately, I developed more congestion symptoms again, including some throat gunk.

With it now being Monday, I’ve begun to cough up more phlegm. This is, in part, because I’ve started to take Mucinex. This mucus is far too thick to cough up without help, at least for me. My Still’s rash is still present, although it continues to fade more a few hours after taking my prednisone burst.

I’ll continue to update here with my experience over the next few days and weeks as necessary.

 

Early September Update

I continued to test positive for COVID until August 25. The last few days were very heavily taxing on my mental health.

My dysautonomia symptoms have drastically returned, too. Not that they were really gone, but they were relatively rare. Now, we’re back to nearly daily incidences of symptoms.

My Still’s Disease is also more active. I’ve had more occurrences of rash, especially following showers.

 

What’s worked well

Your mileage may vary, but this is what has been helpful for me:

  • Having a caring partner, ready and willing to help with literally anything and everything
  • Seeking medical help quickly when needed and being prepared to advocate for myself as needed
  • Mucinex
  • Dye-free Benadryl and anti-itch Benadryl spray
  • Extra anti-histamines (for me, this has meant adding loratadine and the above mentioned Benadryl to my already-daily cetirizine and famotidine)
  • Sitting on a plush blanket to not further anger rash-covered body parts
  • Making sure I eat a little bit every couple of hours, regardless of how hungry I may be
  • Resting in a warm bath
  • Our dogs, who have spent time kissing where my rash has been and cuddling me to help me feel better

Dean sitting on the couch Hank snuggled up by my side

Regardless of whether or not you’ve had COVID yet, please mask. Continue to take other precautions as well, including not meeting in groups even outdoors without masks, washing hands and sanitizing them often, switching out KN95 masks for new ones regularly (at least daily if possible), and possibly using CPC mouthwash and nasal sprays.

Infection numbers are horrible right now and have been for a few weeks.

A map of the United States color-coded in shades of maroon, orange and gray displaying SARS-CoV-2 Wastewater Viral Activity level as of August 1, 2024, where deeper tones correlate to higher viral activity and gray indicates “Insufficient,” or “No Data.” Text above the map reads “Very High” or “High” levels in 44 states. Viral activity is “Moderate” in 4 states, “Low” in 2 states, and data is unavailable for North Dakota, Guam, Puerto Rico, and the U.S. Virgin Islands. At the bottom, text reads People’s CDC. Source: CDC.

People aren’t even testing, thinking they only have allergies or colds. Even for the most healthy person, this is dangerous — but incredibly more so for those of us with underlying health issues.

ACR Responds to Congressional Hearing on Private Practice Challenges

The following is a press release from ACR dated June 24, 2024:

The American College of Rheumatology (ACR) has submitted to the United States House Committee on Ways and Means Health Subcommittee a response to the recent subcommittee hearing, The Collapse of Private Practice: Examining the Challenges Facing Independent Medicine, highlighting issues facing private practices, including inadequate reimbursement for Medicare physicians, burdensome prior authorization policies, and the growing shortage of physicians in the workforce.

In its letter, ACR notes that rising inflation, cuts to reimbursements to below the cost of treating Medicare patients and growing operating costs threaten the viability of private practices. To address these concerns, ACR advocates for legislation to address two persistent challenges impacting Medicare payment to physicians: inflation and a mandatory budget-neutrality requirement. The Strengthening Medicare for Patients and Providers Act (H.R. 2474) would add a permanent annual inflationary update for Medicare physician payments, while the Provider Reimbursement Stability Act (H.R 6371) would help to curtail the negative impact of budget neutrality requirements by raising the current budget neutrality threshold from $20 million to $53 million and requiring its regular re-evaluation.

Given the administrative burden created by costly prior authorization policies, ACR noted its support for efforts to streamline the process so that healthcare team members can spend less time negotiating with insurance companies and more time taking care of patients.

Finally, the shrinking physician workforce creates significant challenges across the healthcare continuum. Unless policymakers intervene, the problem will continue to worsen as fewer physicians are asked to meet the treatment needs of a growing and aging patient population. To address this issue, ACR recommends policies to increase training opportunities, address burnout and early retirement in the healthcare workforce, mitigate the impact of medical education debt, and expand workforce access for visa-holding physicians.

“Private practices are essential to our communities and should be supported by policy,” the letter concludes. “The ACR looks forward to partnering with the Ways & Means Health subcommittee as legislative solutions are considered.”

ACR’s full response letter is available here.